Aphria Inc (APHA) Receives a Buy from Clarus

By Ryan Adsit

Aphria Inc (APHAResearch Report), the Healthcare company, has received a rating update from a Wall Street analyst today. The company received a Buy rating from Clarus’ analyst Noel Atkinson, with a C$22.75 price target.

Atkinson noted:

“We had previously assumed a run-rate of ~$865MM by the end of CY2020; we are now in line with management’s target.”

Atkinson has an average return of 17.4% when recommending Aphria Inc.

According to TipRanks.com, Atkinson is ranked #424 out of 5187 analysts.

Aphria Inc has an analyst consensus of Strong Buy, with a price target consensus of C$15.31, representing a 31.9% upside. In a report released yesterday, PI Financial also maintained a Buy rating on the stock with a C$14 price target.


Aphria Inc’s market cap is currently C$3.88B and has a P/E ratio of 39.4.

The company’s shares closed on Tuesday at C$11.61.